Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

ACC 2024 Congress

Catch up on all the top stories and latest evidence in cardiology research with our ACC 2024 Congress hub page.
ADVANCED SEARCH
Log in
Top
BMC Musculoskeletal Disorders
Published in: BMC Musculoskeletal Disorders 1/2018

Open Access 01-12-2018 | Research article

Expression of MMP-9 decreases metastatic potential of Chondrosarcoma: an immunohistochemical study

Authors: Dominik Malcherczyk, Thomas J. Heyse, Bilal F. El-Zayat, Vanessa Kunzke, Roland Moll, Susanne Fuchs-Winkelmann, Jürgen R. J. Paletta

Published in: BMC Musculoskeletal Disorders | Issue 1/2018

Login to get access

Abstract

Background

Chondrosarcoma is the second most common primary malignant bone tumor. Because of their heterogeneity, with differences in invasive and metastatic behavior, it is important to identify biological markers that will allow for a more accurate estimation of prognosis in patients with these tumors.
Matrix metalloproteinases (MMP) play a crucial role in tumor progression, invasion and metastasis. The mechanism of tumor progression dependent of MMPs is complex and influences malignant transformation, angiogenesis and tumor growth at the primary and metastatic sites. The purpose of this study was to investigate immunohistochemicaly the influence of MMP-1, MMP-3, MMP-9 and MMP-13 expression on prognostic parameter in chondrosarcoma.

Methods

We investigated tissue samples of 28 patients with chondrosarcoma. Immunohistochemical staining to evaluate the expression of MMP-1, MMP-3, MMP-9 and MMP-13 was performed. Subsequently, the expression level was correlated with metastatic potential, histological grading and overall survival in patients with this neoplasm.

Results

In consideration of semi quantitative scoring 64% of chondrosarcoma were scored as positive for MMP-1, 46% for MMP-3, 61% for MMP-9. The specimens had shown no expression of MMP-13. High expression of MMP-9 was associated with better histological differentiation, decreased metastatic potential and favourable overall survival. No correlation was found for expression of MMP-1, MMP-3 or MMP-13.

Conclusions

MMP-1, MMP-3 and MMP-9 are expressed in chondrosarcoma. Our findings suggest that the expression of MMP-9 is associated with clinical outcome parameters in chondrosarcoma.
Literature
1.
2.
Damron TA, Ward WG, Stewart A. Osteosarcoma, chondrosarcoma, and Ewing's sarcoma: national cancer data base report. Clin Orthop Relat Res. 2007;459:40–7.CrossRefPubMed
3.
Lee FY, Mankin HJ, Fondren G, Gebhardt MC, Springfield DS, Rosenberg AE, et al. Chondrosarcoma of bone: an assessment of outcome. J Bone Joint Surg Am. 1999;81(3):326–38.CrossRefPubMed
4.
Ogura K, Fujiwara T, Beppu Y, Chuman H, Yoshida A, Kawano H, et al. Extraskeletal myxoid chondrosarcoma: a review of 23 patients treated at a single referral center with long-term follow-up. Arch Orthop Trauma Surg. 2012;132(10):1379–86.CrossRefPubMed
5.
Heyse TJ, Malcherczyk D, Moll R, Timmesfeld N, Wapelhorst J, Fuchs-Winkelmann S, et al. CD44: survival and metastasis in chondrosarcoma. Osteoarthr Cartil. 2010;18(6):849–56.CrossRefPubMed
6.
Papachristou DJ, Gkretsi V, Rao UN, Papachristou GI, Papaefthymiou OA, Basdra EK, et al. Expression of integrin-linked kinase and its binding partners in chondrosarcoma: association with prognostic significance. Eur J Cancer. 2008;44(16):2518–25.CrossRefPubMedPubMedCentral
7.
Takeuchi A, Yamamoto Y, Tsuneyama K, Cheng C, Yonekura H, Watanabe T, et al. Endogenous secretory receptor for advanced glycation endproducts as a novel prognostic marker in chondrosarcoma. Cancer. 2007;109(12):2532–40.CrossRefPubMed
8.
Yoshimura Y, Isobe K, Arai H, Aoki K, Kito M, Kato H. Preoperative radiographic and histopathologic evaluation of central chondrosarcoma. Arch Orthop Trauma Surg. 2013;133(9):1225–31.CrossRefPubMedPubMedCentral
9.
Friedl P, Wolf K. Tube travel: the role of proteases in individual and collective cancer cell invasion. Cancer Res. 2008;68(18):7247–9.CrossRefPubMed
10.
Klein T, Bischoff R. Physiology and pathophysiology of matrix metalloproteases. Amino Acids. 2011;41(2):271–90.CrossRefPubMed
11.
Martin MD, Matrisian LM. The other side of MMPs: protective roles in tumor progression. Cancer Metastasis Rev. 2007;26(3–4):717–24.CrossRefPubMed
12.
Hua H, Li M, Luo T, Yin Y, Jiang Y. Matrix metalloproteinases in tumorigenesis: an evolving paradigm. Cell Mol Life Sci. 2011;68(23):3853–68.CrossRefPubMed
13.
García MF, González-Reyes S, González LO, Junquera S, Berdize N, Del Casar JM, et al. Comparative study of the expression of metalloproteases and their inhibitors in different localizations within primary tumours and in metastatic lymph nodes of breast cancer. Int J Exp Pathol. 2010;91(4):324–34.CrossRefPubMedPubMedCentral
14.
Dreier R, Grässel S, Fuchs S, Schaumburger J, Bruckner P. Pro-MMP-9 is a specific macrophage product and is activated by osteoarthritic chondrocytes via MMP-3 or a MT1-MMP/MMP-13 cascade. Exp Cell Res. 2004;297(2):303–12.CrossRefPubMed
15.
Deryugina EI, Quigley JP. Matrix metalloproteinases and tumor metastasis. Cancer Metastasis Rev. 2006;25(1):9–34.CrossRefPubMed
16.
Michael M, Babic B, Khokha R, Tsao M, Ho J, Pintilie M, et al. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer. J Clin Oncol. 1999;17(6):1802–8.CrossRefPubMed
17.
Talvensaari-Mattila A, Pääkkö P, Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma. Br J Cancer. 2003;89(7):1270–5.CrossRefPubMedPubMedCentral
18.
Bando E, Yonemura Y, Endou Y, Sasaki T, Taniguchi K, Fujita H, et al. Immunohistochemical study of MT-MMP tissue status in gastric carcinoma and correlation with survival analyzed by univariate and multivariate analysis. Oncol Rep. 1998;5(6):1483–8.PubMed
19.
Agarwal D, Goodison S, Nicholson B, Tarin D, Urquidi V. Expression of matrix metalloproteinase 8 (MMP-8) and tyrosinase-related protein-1 (TYRP-1) correlates with the absence of metastasis in an isogenic human breast cancer model. Differentiation. 2003;71(2):114–25.CrossRefPubMed
20.
McCawley LJ, Crawford HC, King LE, Mudgett J, Matrisian LMA. Protective role for matrix metalloproteinase-3 in squamous cell carcinoma. Cancer Res. 2004;64(19):6965–72.CrossRefPubMed
21.
Noël A, Gutiérrez-Fernández A, Sounni NE, Behrendt N, Maquoi E, Lund IK, et al. New and paradoxical roles of matrix metalloproteinases in the tumor microenvironment. Front Pharmacol. 2012;3:140.PubMedPubMedCentral
22.
Uchibori M, Nishida Y, Nagasaka T, Yamada Y, Nakanishi K, Ishiguro N. Increased expression of membrane-type matrix metalloproteinase-1 is correlated with poor prognosis in patients with osteosarcoma. Int J Oncol. 2006;28(1):33–42.PubMed
23.
Sugita H, Osaka S, Toriyama M, Osaka E, Yoshida Y, Ryu J, et al. Correlation between the histological grade of chondrosarcoma and the expression of MMPs, ADAMTSs and TIMPs. Anticancer Res. 2004;24(6):4079–84.PubMed
24.
Luukkaa H, Klemi P, Leivo I, Mäkitie AA, Irish J, Gilbert R, et al. Expression of matrix metalloproteinase-1, −7, −9, −13, Ki-67, and HER-2 in epithelial-myoepithelial salivary gland cancer. Head Neck. 2010;32(8):1019–27.CrossRefPubMed
25.
Voland P, Besig S, Rad R, Braun T, Baur DM, Perren A, et al. Correlation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase expression in ileal carcinoids, lymph nodes and liver metastasis with prognosis and survival. Neuroendocrinology. 2009;89(1):66–78.CrossRefPubMed
26.
Aresu L, Giantin M, Morello E, Vascellari M, Castagnaro M, Lopparelli R, et al. Matrix metalloproteinases and their inhibitors in canine mammary tumors. BMC Vet Res. 2011;7:33.CrossRefPubMedPubMedCentral
27.
Benassi MS, Gamberi G, Magagnoli G, Molendini L, Ragazzini P, Merli M, et al. Metalloproteinase expression and prognosis in soft tissue sarcomas. Ann Oncol. 2001;12(1):75–80.CrossRefPubMed
28.
Korpi JT, Hagström J, Lehtonen N, Parkkinen J, Sorsa T, Salo T, et al. Expression of matrix metalloproteinases-2, −8, −13, −26, and tissue inhibitors of metalloproteinase-1 in human osteosarcoma. Surg Oncol. 2011;20(1):e18–22.CrossRefPubMed
29.
Söderström M, Aro HT, Ahonen M, Johansson N, Aho A, Ekfors T, et al. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in human chondrosarcomas. APMIS. 2001;109(4):305–15.CrossRefPubMed
30.
Sakamoto A, Oda Y, Iwamoto Y, Tsuneyoshi M. Expression of membrane type 1 matrix metalloproteinase, matrix metalloproteinase 2 and tissue inhibitor of metalloproteinase 2 in human cartilaginous tumors with special emphasis on mesenchymal and dedifferentiated chondrosarcoma. J Cancer Res Clin Oncol. 1999;125(10):541–8.CrossRefPubMed
31.
Scully SP, Berend KR, Qi WN, Harrelson JM. Collagenase specificity in chondrosarcoma metastasis. Braz J Med Biol Res. 1999;32(7):885–9.CrossRefPubMed
32.
Takahashi M, Oka N, Naroda T, Nishitani MA, Kanda K, Kanayama HO, et al. Prognostic significance of matrix metalloproteinases-2 activation ratio in renal cell carcinoma. Int J Urol. 2002;9(10):531–8.CrossRefPubMed
33.
Svagzdys S, Lesauskaite V, Pangonyte D, Saladzinskas Z, Tamelis A, Pavalkis D. Matrix metalloproteinase-9 is a prognostic marker to predict survival of patients who underwent surgery due to rectal carcinoma. Tohoku J Exp Med. 2011;223(1):67–73.CrossRefPubMed
34.
Pozzi A, Moberg PE, Miles LA, Wagner S, Soloway P, Gardner HA. Elevated matrix metalloprotease and angiostatin levels in integrin alpha 1 knockout mice cause reduced tumor vascularization. Proc Natl Acad Sci U S A. 2000;97(5):2202–7.CrossRefPubMedPubMedCentral
35.
Bendrik C, Robertson J, Gauldie J, Dabrosin C. Gene transfer of matrix metalloproteinase-9 induces tumor regression of breast cancer in vivo. Cancer Res. 2008;68(9):3405–12.CrossRefPubMed
36.
Furumatsu T, Yamaguchi N, Nishida K, Kawai A, Kunisada T, Namba M, et al. Endostatin inhibits adhesion of endothelial cells to collagen I via alpha(2)beta(1) integrin, a possible cause of prevention of chondrosarcoma growth. J Biochem. 2002;131(4):619–26.CrossRefPubMed
37.
Hamano Y, Zeisberg M, Sugimoto H, Lively JC, Maeshima Y, Yang C, et al. Physiological levels of tumstatin, a fragment of collagen IV alpha3 chain, are generated by MMP-9 proteolysis and suppress angiogenesis via alphaV beta3 integrin. Cancer Cell. 2003;3(6):589–601.CrossRefPubMedPubMedCentral
Metadata
Title
Expression of MMP-9 decreases metastatic potential of Chondrosarcoma: an immunohistochemical study
Authors
Dominik Malcherczyk
Thomas J. Heyse
Bilal F. El-Zayat
Vanessa Kunzke
Roland Moll
Susanne Fuchs-Winkelmann
Jürgen R. J. Paletta
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Musculoskeletal Disorders / Issue 1/2018
Electronic ISSN: 1471-2474
DOI
https://doi.org/10.1186/s12891-017-1920-7

Other articles of this Issue 1/2018

BMC Musculoskeletal Disorders 1/2018 Go to the issue

Research article

Epidemiology of arthritis, chronic back pain, gout, osteoporosis, spondyloarthropathies and rheumatoid arthritis among 1.5 million patients in Australian general practice: NPS MedicineWise MedicineInsight dataset

Research article

Short- and long-term reproducibility of diffusion-weighted magnetic resonance imaging of lower extremity musculature in asymptomatic individuals and a comparison to individuals with spinal cord injury

Study protocol

Facilitating physical activity and reducing symptoms in patients with knee osteoarthritis: study protocol of a randomized controlled trial to test a theory-based PrevOP-psychological adherence program (PrevOP-PAP)

Research article

The effect of autologous platelet rich plasma on tenocytes of the human rotator cuff

Correction

Correction to: Arthroscopic release using F and C method versus conventional open release method in the treatment of gluteal muscle contracture: a comparative study

Study protocol

Routine versus on demand removal of the syndesmotic screw; a protocol for an international randomised controlled trial (RODEO-trial)